Antiemetic Tablets Prove Equal in Efficacy to IV Drug Regimen

Oncology NEWS InternationalOncology NEWS International Vol 6 No 7
Volume 6
Issue 7

ASCO--Two randomized trials have shown that an oral serotonin antagonist, granisetron (Kytril) tablets, is equal in safety and efficacy to an intravenous drug of the same class in preventing emesis in patients undergoing emetogenic chemotherapy.

ASCO--Two randomized trials have shown that an oral serotonin antagonist,granisetron (Kytril) tablets, is equal in safety and efficacy to an intravenousdrug of the same class in preventing emesis in patients undergoing emetogenicchemotherapy.

In the first study, of highly emetogenic chemotherapy, presented atASCO by Richard Gralla, MD, 1,054 patients received either two 1 mg granisetrontablets 60 minutes before an initial course of cisplatin (Platinol) or32 mg of IV ondansetron (Zofran) 30 minutes before cisplatin administration.Placebos were given to allow for blindedness.

Total control rates (defined as no nausea or vomiting and no additionalmedication) at 24 hours were comparable for both groups: 55% for oral granisetronand 58% for IV ondansetron.

"It is clear that Kytril tablets offer control of nausea and vomitingcomparable to intravenous therapy," said Dr. Gralla, director, OschnerCancer Institute, New Orleans. He also noted that in this study, the costof the oral agent ($62) was lower than that of the IV drug ($129).

In the second trial, involving moderately emetogenic chemotherapy, thesame drug regimens were given to 1,085 patients prior to an initial courseof cyclophosphamide or carboplatin (Paraplatin). Again, total control rateswere similar, said Edith Perez, MD, associate professor of medicine, MayoClinic Jacksonville (Florida), in her ASCO presentation.

At 24 hours, 59% of patients on the oral agent had achieved total control,compared with 58% of those on IV ondansetron. At 48 hours, the figureswere 47% and 44%, respectively.

In the cisplatin study, the most common adverse events--headache, asthenia,and constipation--were similar in both antiemetic groups. In the cyclophosphamide/carboplatintrial, the incidence of these side effects was similar in both groups,while IV ondansetron-treated patients had a significantly higher incidenceof dizziness and visual disturbances.

Related Videos
Experts on multiple myeloma
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Experts on multiple myeloma
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
Experts on MM
Experts on colorectal cancer
Experts on MM
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Experts on multiple myeloma